LITESPARK-012 Trial Falls Short in Advanced Kidney Cancer

New results from the phase 3 LITESPARK-012 trial show that adding additional therapies to a current standard treatment did not improve outcomes for patients with advanced renal cell carcinoma, the most common type of kidney cancer. The study evaluated two experimental combination approaches in the first-line setting, meaning they were given as the initial treatment after diagnosis of advanced disease.

According to findings released by Merck and Eisai, neither of the tested combinations significantly improved overall survival or delayed disease progression compared with an already approved regimen. These results suggest that the current standard of care remains an important option for patients, and that further research is still needed to identify more effective first-line therapies.

Key trial results show no survival benefit

The LITESPARK-012 trial tested two different treatment combinations. One included the addition of Welireg (belzutifan) to Keytruda (pembrolizumab) and Lenvima (lenvatinib), while the other evaluated Lenvima combined with a co-formulation of Keytruda and the investigational antibody quavonlimab (MK-1308).

At the time of an interim analysis, neither treatment approach met the study’s primary goals. Specifically, the combinations did not significantly improve overall survival, which measures how long patients live after starting treatment. They also did not significantly reduce the risk of disease progression or death compared with the existing combination of Keytruda plus Lenvima.

However, it is important to note that safety results were consistent with what has been observed in earlier studies, meaning no unexpected side effects emerged. Researchers continue to analyze the data to better understand these outcomes.

Understanding advanced renal cell carcinoma

Renal cell carcinoma accounts for approximately 80% of kidney cancer cases. Many patients are diagnosed at an advanced stage, when the disease has spread beyond the kidney and requires systemic treatment.

Over the past decade, treatment has shifted toward combination approaches that include immunotherapy and targeted therapies. One such regimen, Keytruda plus Lenvima, is already approved in the United States and other regions as a first-line treatment for advanced disease.

Welireg, one of the drugs studied in LITESPARK-012, is a hypoxia-inducible factor-2 alpha inhibitor. It has shown activity in previously treated kidney cancer and in certain genetic conditions, which led researchers to explore whether adding it earlier in treatment could further improve outcomes.

How the trial was conducted

The phase 3 LITESPARK-012 study was designed to evaluate whether adding new therapies to existing regimens could improve outcomes for patients receiving their first treatment for advanced renal cell carcinoma.

Participants were randomly assigned to receive one of the experimental combinations or the current standard regimen. The primary goals of the study included overall survival and progression-free survival, which measures how long patients live without their disease worsening.

An interim analysis was conducted to assess whether the treatments were meeting these goals. Based on this analysis, neither experimental approach demonstrated a statistically significant benefit over the standard treatment.

The trial enrolled a large group of patients with advanced renal cell carcinoma, reflecting a real-world population of individuals starting first-line therapy. In total, approximately 1,600 patients took part in the study, allowing researchers to evaluate the effectiveness and safety of the treatment combinations across a broad patient population.

Patients included those with clear cell renal cell carcinoma, the most common subtype of the disease. This helps ensure that the findings are relevant to a majority of individuals diagnosed with advanced kidney cancer.

Additional insights and what comes next

Although the trial did not meet its primary endpoints, the findings remain important for guiding future research. The results suggest that simply adding another drug to an already effective combination may not always lead to better outcomes.

Researchers will continue to analyze the data to identify whether certain subgroups of patients may still benefit from these combinations. At the same time, ongoing clinical trials are exploring other strategies to improve first-line treatment options for advanced renal cell carcinoma.

For patients, these results reinforce the importance of discussing all available treatment options with their care team. Established therapies continue to offer meaningful benefit, and clinical trials remain a key pathway for accessing emerging treatments.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

References

1. "Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)," by Merck. News; April 21, 2026.
2. "FDA Approves Keytruda Plus Lenvima for Frontline RCC Treatment," by Brielle Benyon. CURE; Aug. 12, 2021. https://www.curetoday.com/view/fda-approves-keytruda-plus-lenvima-for-frontline-rcc-treatment.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.